Axiom Clinical Research of Florida - Neurology Research, Tampa, FL

Clinical Trials

Neurology Trials || Internal Medicine Trials

1993 – 1995	Tampa General Hospital: Phase IV Use of Felbamate Clinical Trial
1993 – 1995	Glaxo: Phase IV Treatment of Serious or Life-Threatening Epilepsy Clinical Trial
1993 – 1998	Syntex-Synergen: Phase III Natural History Study Trial Amyotrophic Lateral Sclerosis (ALS)
1993 – 1998	Syntext-Synergen: Phase III Amyotrophic Lateral Sclerosis (ALS) Clinical Trial
1993 – 2000	Syntex-Synergen: Phase III Amyotrophic Lateral Sclerosis (ALS) Clinical Trial
1993 – 1995	Glaxo Pharmaceuticals: Phase III Migraine Attack Clinical Trial
1996 – 1997	Glaxo Pharmaceuticals: Phase III Multiple Migraine Attack Clinical Trial
1996 – 1998	Amgen-Regeneron: Phase II Amyotrohpic Lateral Sclerosis (ALS) Clinical Trial
1997 – 1999	Genentech: Phase III Acute Ischemic Stroke Clinical Trial
1998 – 1999	Marrion-Merrell-Dow: Phase II Partial Seizures Clinical Trial
1998 – 1999	Forest Laboratories: Phase III Dementia of Alzheimer's Type Clinical Trial
1998 – 1999	Sandoz Pharmaceuticals: Phase III Acute Migraine Attack Clinical Trial
1998 – 2000	Eisai America: Phase III Alzheimer's Disease Clinical Trial
1998 – 2000	Glaxo-Wellcome: Phase III Productivity Loss Due to Migraine Clinical Trial
1998 – 2000	Amgen-Regeneron: Phase II Amyotrophic Lateral Sclerosis (ALS) Clinical Trial
1998 – 2000	Scherer DDS: Phase II Control of Symptoms of Parkinson's Disease Clinical Trial
1998 – 2000	Zeneca: Phase III Acute Treatment of Multiple Migraine Headaches Clinical Trial
1998 – 2000	Athena Neurosciences: Phase III Treatment of Spasticity Associated with Chronic Stroke Clinical Trial
1998 – 2005	Indiana University: Registry of Arrhythmias in Myotonic Muscular Dystrophy Clinical Trial
1999 – 2000	Glaxo Pharmaceuticals: Phase III Acute Treatment of a Single Migraine Attack Clinical Trial
1999 – 2001	Scherer DDS/Harris Clinical Research: Phase II Control of Symptoms in Parkinson's Disease Clinical Trial
1999 – 2001	Glaxo Wellcome: Phase III Acute Treatment of Migraine Clinical Trial
1999 – 2001	Cephalon: Phase III Myotrophin Injection in Patients with Amyotrophic Lateral Sclerosis Clinical Trial
1999 – 2001	Bristol-Myers-Squibb: Phase III Patients with Acute Stroke Clinical Trial
2000 – 2001	Glaxo Pharmaceuticals: Phase III Acute Treatment of Four Migraine Attacks Clinical Trial
2000 – 2001	Boehringer Ingelheim Pharmaceuticals: Phase II-III Acute Ischemic Stroke Clinical Trial
2000 – 2002	Bayer Pharmaceuticals: Phase III Dementia of the Alzheimer's Type Clinical Trial
2000 – 2002	Scherer DDS/MDS Harris: Phase III Management of Parkinsonian Patients Being Treated with Levodopa Clinical Trial
2000 – 2002	Hoechst Marion Roussel: Phase IV Use of Sabril in Patients with Partial Seizures Clinical Trial
2000 – 2002	Athena Neurosciences: Phase III Treatment of Spasticity Associated with Chronic Stroke Clinical Trial
2000 – 2002	AstraZeneca: Phase IV Effect of Zomig and Usual Migraine Care on Work Loss Productivity and Patient Preference Clinical Trial
2000 – 2002	AstraZeneca CNS Research: Phase IV Acute Treatment of Migraine Headaches in Adolescent Subjects Clinical Trial
2001 – 2002	Athena Neurosciences: Phase III Initiation of Therapy in Patients with Partial Seizures
2001 – 2002	NeoTherapeutics: Phase III Patients with Probable Alzheimer's Disease Clinical Trial
2001 – 2003	Novartis: Phase III Adjunctive Therapy in Children and Adults with Inadequately Controlled Partial Seizures Clinical Trial
2001 – 2003	Scherer DDS: Phase III Management of Parkinsonian Patients Being Treated with Levodopa Clinical Trial
2001 – 2003	Parke-Davis Pharmaceutical Research: Phase III Pregabalin Safety and Efficacy in Patients with Partial Seizures
2001 – 2003	Proctor & Gamble: Phase III Treatment of Acute Migraine Headache With or Without Aura Clinical Trial
2001 – 2003	Neotherapeutics: Phase III Probable Alzheimer's Disease Clinical Trial
2001 – 2003	Johnson & Johnson: Phase III Treatment of Dementia Secondary to Cerebrovascular Disease Clinical Trial
2001 – 2003	Bristol-Myers-Squibb: Phase III Demential of The Alzheimer's Type Clinical Trial
2001 – 2003	Cephalon: Phase IV Partial Onset Seizures Clinical Trial
2001 – 2003	Sanwa Kagaku Kenkyusho Co. Ltd.: Phase II Diabetic Neuropathy Clinical Trial
2001 – 2003	Glaxo SmithKline: Phase III Painful Diabetic Neuropathy Clinical Trial
2001 – 2003	Johnson & Johnson Research Foundation: Phase III Treatment of Dementia Secondary to Cerebrovascular Disease Clinical Trial
2002 – 2003	Neurocrine Biosciences: Phase II Primary Insomnia Type Clinical Trial
2002 – 2004	Suntory: Phase III Acute Ischemic Stroke Clinical Trial
2002 – 2004	Johnson & Johnson: Phase II Treatment of Psychosis of Alzheimer's Disease Clinical Trial
2002 – 2004	Serono: Phase III Tolerability of Rebif Injection With and Without the Use of Rebiject Mini in Relapsing Remitting MS Patients Clinical Trial
2002 – 2004	Biogen: Phase III Avonex Treatment in Patients with Relapsing Multiple Sclerosis (AIMS) Clinical Trial
2002 – 2004	Pharmacia: Phase III Early Parkinson's Disease Clinical Trial
2002 – 2004	AstraZeneca: Phase III Treatment of Adult Subjects with Migraine Clinical Trial
2003 – 2004	SeraCare Life Sciences: BioBank Repository: Collection of Blood, Plasma and Leukocytes with Matching Demographic, Clinical and Medical History
2003 -2004	Quigley Pharmaceuticals: Phase II Excessive Salivary Secretions Clinical Trial
2003 – 2004	GSK: Phase III Restless Leg Syndrome (RLS) Clinical Trial
2003 – 2004	PrecisionMed: Late Onset Alzheimer's Disease, Genomic Trial
2003 – 2005	ONO Pharmaceuticals: Phase III Acute Ischemic Stroke Clinical Trial
2003 – 2006	Berlex Laboratories: Phase III Relapsing Remitting Multiple Sclerosis Clinical Trial
2003 – Present	Berlex Laboratories: Phase III Relapsing Remitting Multiple Sclerosis Clinical Trial
2003 – 2004	PrecisionMed: Early Onset Alzheimer's Disease, Genomic Trial
2003 – 2004	TAKEDA: Phase III Chronic Insomnia (Adult Subjects) Clinical Trial
2003 – 2004	TAKEDA: Phase III Chronic Insomnia (Elderly Subjects) Clinical Trial
2003 – 2004	Glaxo-Smith Kline: Phase III Epilepsy Clinical Trial
2004 – 2005	TAKEDA: Phase III Chronic Insomnia (Subjects) Clinical Trial
2004 – 2005	AstraZeneca: Phase III Treatment of Agitation Associated with Dementia (STAR Trial) Clinical Trial
2004 – 2005	PPD Development: Phase III Adult Primary Insomnia Patient with Sleep Maintenance Difficulties Clinical Trial
2004 – 2005	Pfizer: Phase III Postherpetic Neuralgia (PNN) Clinical Trial
2004 – 2005	Glaxo-Smith Kline: Phase III Partial Seizures Clinical Trial
2004 – 2005	Glaxo-Smith Kline: Phase III Restless Leg Syndrome Requiring Extended Treatment Coverage (RLS) Clinical Trial
2004 – 2006	Sanofi-Synthelabo Research: Phase II CHARISMA Clinical Trial
2004 – Present	Genentech, Inc: Phase II-III Primary Progressive Multiple Sclerosis Clinical Trial
2004 – Present	Neurochem, Inc: Phase III Mild-to-Moderate Alzheimer's Disease Clinical Trial
2004 – Present	Myriad Pharmaceuticals: Phase III Dementia of the Alzheimer's Type Clinical Trial
2004 – Present	ONO Pharm, USA Inc: Phase II Mild-to-Moderate Alzheimer's Disease Clinical Trial
2004 - Present	Genzyme Corporation: Phase II Early, Active Relapsing-Remitting Multiple Sclerosis
2005 – 2006	Vernalis Development, Ltd.: Phase III Prevention of Menstrually-Related Migraine (MRM) Clinical Trial
2005 – Present	Boehringer Ingelheim Pharmaceuticals: Phase IV Open Label Ophthalmologic Safety Clinical Trial in Early Parkinson's Disease
2005 – 2006	Eisai/Pfizer, Inc.: Phase IV Open Label Safety and Effectiveness in Hispanic Mild to Moderate Alzheimer's Disease
2005 – 2006	Endo Pharmaceuticals: Phase IV Effectiveness and Safety for Acute Treatment of Menstrual Migraines
2005 – 2006	Hamilton Pharmaceuticals, Inc.: Phase III Randomized Controlled Comparison Study of Patients with Post-Stroke Apathy
2005 – 2007	GlaxoSmithKline: Phase III Randomized Double Blind Cohort Study on Safety and Tolerability in Patients with Restless Legs Syndrome (RLS)
2006 – Present	GlaxoSmithKline: Phase III Open Label Study on Safety in Patients with Restless Legs Syndrome (RLS)
2006 – Present	Biogen Idec: Genomic Biomarker Response in Multiple Sclerosis Patients
2006 – 2006	Genomics Collaborative: Genomic, Serologic, Metabolic, and Proteomic Clinical Study in Multiple Sclerosis Patients
2006 – 2006	Somaxon Pharmaceuticals, Inc.: Phase III Randomized Double Blind Efficacy and Safety Study in Elderly Patients with Primary Sleep Maintenance Insomnia
2006 – 2007	XenoPort, Inc.: Phase II Randomized Double Blind Efficacy and Safety Study in Patients with Restless Legs Syndrome (RLS)
2006 – Present	XenoPort, Inc.: Phase II Open Label Efficacy an Safety Study in Patients with Restless Legs Syndrome (RLS)
2006 – Present	ENDO Pharmaceuticals: Phase III Randomized Double Blind Safety and Efficacy of Lidocaine Patch 5% in Patients with Carpal Tunnel Syndrome
2006 – Present	St. Jude Medical, Inc.: Device Trial on Atrial PFO Closure in Migraine Subjects
2006 – Present	GlaxoSmithKline, Inc.: Study of Combination Product in Migraine Subjects with Poor Response to Eletriptan
2006 – Present	Memory Pharmaceuticals Corporation: Multicenter Randomized Study on Safety and Efficacy in Patients with Mild to Moderate Alzheimer's
2006 – Present	Merck & Company: Multicenter, Randomized Double Blind Study in Patients with Primary Hypercholesterolemia or Mixed Hyperlipidemia
2006 – Present	Cognition Pharmaceuticals, Inc.: Dose Titration Study in Persons with Multiple Sclerosis with Cognitive Impairment
2006 – Present	Myriad Pharmaceuticals, Inc.: Open Label Study in Subjects with Dementia of the Alzheimer's Type
2006 – Present	Myriad Pharmaceuticals, Inc.: Phase III Multinational, Randomized, Double Blind Study on Measures of Cognition, Activities of Daily Living and Global Function in Subjects with Mild Dementia of the Alzheimer's Type
2006 – Present	Neurochem, Inc.: Open Label Extension in Patients with Alzheimer's Disease
2006 – Present	Novartis Pharmaceuticals Corporation: Efficacy and Safety Study of Orally Administered Medication in Patients with Relapsing-Remitting Multiple Sclerosis
2006 – Present	Novartis Pharmaceuticals Corporation: Efficacy and Safety Study of Orally Administered Medication versus Interferon B-1a in Patients with Relapsing-Remitting Multiple Sclerosis
2006 – Present	Teva Neuroscience, Inc.: Randomized Open Label Study Evaluating Scheduled Neutralizing Antibody Testing on Treatment Patterns in Multiple Sclerosis Patients
2006 – Present	XenoPort, Inc.: Open Label Extension Safety and Efficacy Study in Patients with Restless Legs Syndrome
2007 – Present	XenoPort, Inc.: Phase II Randomized Double Blind Placebo Controlled Dose Response Efficacy and Pharmacokinetics Study in Patients with Restless Legs Syndrome (RLS)
2007 – Present	Serono, Inc.: Phase II Safety, Tolerability, and Efficacy Study of Add-on Orally Administered Medication in Multiple Sclerosis Patients with Active Disease
2007 – Present	Serono, Inc.: Phase III b Randomized, Multicenter Open Label Study in IFN-Naïve Subjects with Relapsing-Remitting Multiple Sclerosis
2007 - Present	Bayer, Inc.: Phase III b International, Multicenter, Open Label Relapsing-Remitting Multiple Sclerosis Clinical Trial
2007 - Present	Genzyme Corporation: Phase III Relapsing-Remitting Multiple Sclerosis Clinical Trial
2007 - Present	Novartis Pharmaceuticals Corporation.: Open Label, Randomized, Multicenter, Parallel Group Study in Patients with Probable Alzheimer's Disease
2007 - Present	Takeda Global Research & Development Center, Inc.: Randomized, Double Blind Parallel Group Study in Adult Patients with Chronic Insomnia

Updated 08/07

[ back to top ]

Internal Medicine Trials

1995 - 1996	Pfizer Phase IV Hypertensive Clinical Trial
1993 - 1996	Sankyo/Parexel Phase III Hypertensive Clinical Trial
1994 - 1996	Bristol-Myers Squibb Phase III Hypertensive Clinical Trial
1995 - 1996	Bristol-Myers Squibb Phase II Severe Hypertensive Clinical Trial
1995 - 1996	Boehringer Ingelheim Phase III Hypertensive Clinical Trial
1995 - 1996	Knoll Pharmaceutical Phase III Hypertensive Clinical Trial
1995 - 1996	Cambridge NeuroScience, Inc. Phase III Closed Head Trauma Neuroprotector Clinical Trial
1995 - 1996	Amgen, Inc. Phase IV CHF in Chronic Hemodialysis Patients
1995 - 1997	Scios Nova, Inc. Phase III Oliguric Acute Tubular Necrosis Clinical Trial
1995 - 1997	Boehringer Ingelheim Phase III ACE-Induced Cough Hypertensive Clinical Trial
1996 - 1997	Elan/Parexel Phase IV Hypertensive Clinical Trial
1996 - 1997	Merck & Co. Phase IV Factorial Hypertensive Clinical Trial
1997 - 1997	Elan/SciRex Phase IV Hypertensive Clinical Trial
1994 - 1997	SmithKline Beecham Phase II Hypertensive Clinical Trial
1995 - 1998	Parke-Davis Phase III Acute Ischemic Stroke Clinical Trial
1995 - 2001	Bristol-Myers Squibb Phase III Diabetic Nephropathy Clinical Trial
1996 - 2001	Merck & Co. Phase IV Hypertensive in LVH Clinical Trial
1997 - 1998	Searle, Inc. Phase IV Hypertensive Clinical Trial
1997 - 1999	Searle, Inc. Phase II Hypertensive Clinical Trial
1997 - 1998	Pfizer, Inc. Phase IV Isolated Systolic Hypertensive Clinical Trial
1997 - 2000	Amylin Phase III Insulin Dependent Clinical Trial
1997 - 1998	Bristol-Myers Squibb Phase II Hypertensive Clinical Trial
1997 - 1998	Bristol Myers Squibb Phase III Hypertensive Clinical Trial
1997 - 1999	Bristol Myers Squibb Phase III Hypertensive Clinical Trial
1997 - 2001	Sankyo Phase III Hypertensive Clinical Trial
1997 - 2001	Sankyo Phase III Hypertensive Clinical Trial
1997 - 1999	Whitehall-Robins Phase IV Hypertensive Clinical Trial
1997 - 1999	Bayer Phase III NIDDM Clinical Trial
1998 - 1999	Tap, Inc. Phase III Community Acquired Pneumonia Clinical Trial
1998 - 1999	Takeda America, Inc. Phase III NIDDM Clinical Trial
1998 - 2000	Novartis, Inc. Phase IV Hypercholesterolemia Clinical Trial
1998 - 2001	Elan Pharmaceuticals, Phase II Moderate to Severe Neuropathic Pain Clinical Trial
1998 - 2001	Novartis, Inc. Phase III Post Myocardial Infarction Clinical Trial
1999 - 2001	Knoll Pharmaceuticals, Phase III Anti-Arrhythmic Clinical Trial
1999 - 2001	Medco, Inc. Flo-Wire Clinical Trial
1999 - 2001	Acetelion, Inc. Phase III Congestive Heart Failure Clinical Trial
1999 - 2001	SmithKlineBeecham, Phase III Congestive Heart Failure Clinical Trial
2000 - 2001	BioPure, Inc., Phase II Blood Substitute Clinical Trial
2000 - 2001	Bristol Myers Squibb, Phase III Hypertensive with CHF Component Clinical Trial
2000 - 2001	Bristol Myers Squibb, Phase III Angioedema Clinical Trial
2000 - 2001	Merck, Inc. Phase III Hypertensive with LVH Clinical Trial
2000 - 2001	Sugen, Inc., Phase II Colorectal Cancer Clinical Trial
2000 - 2001	CATO, Inc., Phase II Non-Small Cell Lung Cancer Clinical Trial
2000 - 2001	Senju, Inc., Phase III Conjunctivitis Clinical Trial
2000 - 2001	Pfizer, Inc., Phase II Inhaled Insulin Clinical Trial
2000 - 2001	Pharmacia-Upjohn Phase III Depression Clinical Trial
2000 - 2001	Pharmacia-Upjohn Phase II Oral Diabetic Agent Clinical Trial
2000 - 2001	Novo Nordisk, Inc., Phase III Diabetic Agent Clinical Trial
2000 - 2001	Bayer, Inc., Phase IV Pediatric Quinolone Clinical Trial
2000 - 2001	AstraZeneca, Inc., Phase III Hyperlipidemia with Cardiac Component Clinical Trial
2000 - 2001	Eli Lilly, Co., Phase IV Human Growth Hormone Clinical Trial
2000 - 2001	Amgen, Inc., Phase III NESP in Hemodialysis Patients Clinical Trial Agent Clinical Trial
2000 - 2001	KOS, Inc., Phase III Hypertensive Clinical Trial
2005 - 2006	Merck, Inc., Phase III Hypercholesterolemia/Mixed Dyslipidemia Clinical Trial
2006 - 2007	Merck, Inc., Phase III Open Label Hypercholesterolemia/Mixed Dyslipidemia Clinical Trial
2007 - Present	Merck, Inc., Phase III Hypercholesterolemia/Mixed Dyslipidemia Clinical Trial
2007 - Present	Merck, Inc., Phase III Oral Diabetic Agent Clinical Trial
2007 - Present	Eli Lilly Co., Phase III Injectible Diabetic Agent Clinical Trial

[ back to top ]